BADDI: Artificial intelligence in screening with standard mammography and tomosynthesis

The BADDI-project will add knowledge about the use of artificial intelligence to detect breast cancer in screening with standard mammography and with tomosynthesis.

Can artificial intelligence increase accuracy and effectiveness of breast cancer screening?

A research project aimed at investigating whether artificial intelligence can help the radiologists in BreastScreen Norway to become even more precise and effective in their search for breast cancer in women.

Cancer among Norwegian offshore workers

It is well known that some of the chemical components in petroleum and its derivates can be carcinogenic. The purpose of these studies is to study the incidence of cancer among Norwegian offshore workers and to study possible relationships between exposure from the working environment and cancer risk.

Cancer and pregnancy

Do cancer during pregnancy influence the prognosis? Is the risk of pregnancy and delivery complications increased for women with pregnancies after cancer? If pre-eclampsia have protective effects on the life-time risk of getting breast cancer, do breast cancer survivors with a history of pre-eclampsia have a better prognosis than those without pre-eclampsia in the past?

Cancer patient pathways in Norway

The study aims to investigate whether the introduction of cancer patient pathways has led to a change in waiting times, differences in access to treatment and whether health care is the same regardless of the patients' place of residence.

Effectiveness of tomosynthesis in breast cancer screening

This international study will investigate whether tomosynthesis is a better screening tool for breast cancer than standard mammography.

EULAT Eradicate Gallbladder Cancer

EULAT Eradicate Gallbladder Cancer (GBC) aims to improve the prevention, early detection and treatment of gallbladder cancer. The Cancer Registry of Norway is responsible for work package (WP) 3: Novel biomarkers for GBC risk prediction and early detection.

How quickly do breast cancers grow?

This project will use data from BreastScreen Norway to develop statistical models that can contribute to an increased understanding of the development of breast cancer tumours and women's survival of breast cancer.

Sequencing HPV for biomarker discovery

HPVseq is an cross-institutional research group with three the main goals, To discover HPV biomarkers, delineate HPV evolution and develop HPV detection and characterization methods.

HPV-related research

Human Papillomavirus (HPV) is a very common group of viruses that, in the most severe cases, can lead to cancer in the cervix, as well as other organs. The Cancer Registry is involved in several projects that aim to increase knowledge about HPV.


This project will examine the effect of using the assumed mother tongue as the language of cancer screening invitation and information on attendance in immigrant groups, as well as investigate reasons why immigrants attend or not in organized screening for colorectal cancer.

JanusRNA - identification of early cancer biomarkers

RNA are involved in numerous cellular processes in cancer development. We are currently investigating RNA as early detection and potential screening biomarkers of cancer.

Long-term effects following treatment of screen-detected versus symptomatic breast cancer

In this postdoctoral project, we will investigate whether the long-term quality of life among breast cancer survivors is better in women with breast cancer detected by screening mammography compared to women with breast cancer detected due to symptoms.

LTFU: Long-term follow up of subjects participating in the clinical trials of the HPV-vaccine

LTFU evaluates the long-term effectiveness, immunogenocity and safety of the HPV-vaccines Gardasil and Gardasil-9.

Machine Learning in BreastScreen Norway

- A research project aimed at improving the efficiency and quality of the national screening program – BreastScreen Norway - by combining automatic image analysis and radiological expertise.

The microbiome as a colorectal cancer screening biomarker (CRCbiome)

Presence of certain bacteria in the gut are strongly associated with colorectal cancer. This project aims to discover gut microbiota biomarkers for colorectal cancer screening.

New cancer treatment and survival

The number of cancer survivors is increasing and this is partly due to improved cancer treatment. In this study, we investigate whether new, expensive cancer treatments reduce the need for other palliative treatments and how much new cancer drugs increase overall survival in the population.

Nordpred: Prediction of cancer incidence in the Nordic countries up to the year 2020

The Nordic cancer registries have carried out a larger study to calculate the cancer incidence in the Nordic countries up through the year 2020. In this study the number of new cancer cases in Norway is estimated to increase with 42% for males and 36% for females. The escalation in cancer cases is mainly due to the ageing of the population, while a smaller part of the increase are due to an increase in risk.

A randomized study on colorectal cancer screening (NORCCAP)

NORCCAP (Norwegian Colorectal Cancer Prevention) is a randomized study on screening for colorectal cancer (CRC) and adenomatous polyps (potential precursor lesions for colorectal cancer).

Patient reported outcomes after treatment for colorectal cancer – A prospective nationwide study from The Norwegian Colorectal Cancer Registry

The aim of this project is to evaluate the patient-reported outcomes including functional outcomes, late adverse effects and health-related quality of life in patients treated for colorecal cancer (CRC) in Norway.

Personalizing colorectal cancer screening by lifestyle

Colorectal cancer screening reduces the incidence and mortality of cancer. However, many people need to go through the screening examination without having a cancer or precursors of cancer. Screening programmes practice “one-size fits all” approach and use only age as risk factor. This project investigates whether colorectal cancer screening can be improved by including lifestyle information from participants, personalizing screening to fit the individual’s risk profile.

Physical activity, fitness and cancer

Based on data from the "Oslo Ischemia Cohort" and The Cancer Registry of Norway, this study aim to assess relationships between physical activity, fitness and cancer.

Prescribed drugs and cutaneous melanoma

Sun exposure is the most important risk factor of cutaneous melanoma, but several studies have suggested that some prescripted drugs also may play a part. This project aims to investigaste if prescripted drugs influence the risk of, and death due to cutaneous melanoma and provide better and more targeted prevention of cutaneous melanoma through the identification of high-risk persons.

SARS-CoV-2 in cancer patients

The project wants to shed light on cancer patients' risk of coronavirus infection and whether these patients are exposed to a more severe course and death than the rest of the population.

The impact of obesity and circulating small RNA in the development of endometrial cancer

The project will investigate circulating RNAs as novel diagnostic and prognostic cancer biomarkers, and how age and life-style factors such as body mass index influence their expression levels, using pre-diagnostic samples from the Janus Serum Bank.

Tomosynthesis – the future screening tool for breast cancer?

The tomosynthesis studies in Bergen, the To-Be studies, are aimed at investigating whether screening with digital breast tomosynthesis is a better screening tool than standard digital mammography for BreastScreen Norway.

Vitamin D, obesity and cutaneous malignant melanoma

Cutaneous Malignant Melanoma is largely caused by exposure to ultraviolet radiation (UVR). UVR is also our main source of vitamin D,which have been associated with reduced risk of some cancers. The situation for melanoma is unclear, as both low and high vitamin D levels have been associated with increased risk.